Concepts (171)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Selective Estrogen Receptor Modulators | 9 | 2021 | 128 | 1.900 |
Why?
|
| Tamoxifen | 10 | 2021 | 875 | 1.490 |
Why?
|
| Postmenopause | 2 | 2020 | 375 | 1.150 |
Why?
|
| Breast Neoplasms | 22 | 2021 | 16238 | 1.120 |
Why?
|
| Receptors, Estrogen | 6 | 2019 | 2177 | 1.010 |
Why?
|
| Raloxifene Hydrochloride | 4 | 2021 | 46 | 0.870 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2020 | 95 | 0.690 |
Why?
|
| Estrogen Antagonists | 2 | 2018 | 188 | 0.650 |
Why?
|
| Women's Health | 1 | 2020 | 197 | 0.640 |
Why?
|
| Drug Discovery | 1 | 2019 | 329 | 0.540 |
Why?
|
| Chemoprevention | 2 | 2017 | 251 | 0.520 |
Why?
|
| Estradiol Congeners | 1 | 2014 | 7 | 0.490 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2016 | 255 | 0.470 |
Why?
|
| Fluorouracil | 1 | 2016 | 1990 | 0.380 |
Why?
|
| Models, Biological | 1 | 2019 | 3189 | 0.350 |
Why?
|
| Neoplasms, Hormone-Dependent | 3 | 2010 | 347 | 0.320 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2013 | 841 | 0.280 |
Why?
|
| Estrogens | 3 | 2013 | 807 | 0.210 |
Why?
|
| Apoptosis | 3 | 2014 | 7755 | 0.200 |
Why?
|
| Female | 23 | 2021 | 149120 | 0.190 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2002 | 550 | 0.160 |
Why?
|
| American Cancer Society | 1 | 2019 | 35 | 0.160 |
Why?
|
| Students | 1 | 2021 | 335 | 0.160 |
Why?
|
| Nuclear Receptor Co-Repressor 2 | 1 | 2018 | 46 | 0.150 |
Why?
|
| Humans | 23 | 2021 | 271093 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2018 | 5417 | 0.140 |
Why?
|
| Receptors, Progesterone | 1 | 2002 | 1610 | 0.140 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 14636 | 0.130 |
Why?
|
| Precancerous Conditions | 1 | 2002 | 1061 | 0.130 |
Why?
|
| Aromatase Inhibitors | 1 | 2018 | 311 | 0.130 |
Why?
|
| Aspartic Acid | 1 | 2015 | 136 | 0.120 |
Why?
|
| Estrogen Receptor beta | 2 | 2012 | 149 | 0.110 |
Why?
|
| Tyrosine | 1 | 2015 | 503 | 0.110 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2013 | 45 | 0.110 |
Why?
|
| Incidence | 3 | 2020 | 5841 | 0.110 |
Why?
|
| Heterografts | 1 | 2015 | 738 | 0.100 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 2051 | 0.100 |
Why?
|
| Glycoproteins | 1 | 2013 | 778 | 0.080 |
Why?
|
| Animals | 9 | 2021 | 61554 | 0.080 |
Why?
|
| Estrogen Receptor alpha | 4 | 2006 | 692 | 0.080 |
Why?
|
| Carrier Proteins | 2 | 2013 | 2085 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2021 | 39951 | 0.070 |
Why?
|
| Mitochondria | 1 | 2012 | 1292 | 0.060 |
Why?
|
| Protein Isoforms | 1 | 2007 | 843 | 0.060 |
Why?
|
| Oncogene Proteins | 1 | 2005 | 367 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 10400 | 0.050 |
Why?
|
| Aldosterone | 1 | 2002 | 78 | 0.050 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2002 | 128 | 0.050 |
Why?
|
| Cell Survival | 1 | 2009 | 3058 | 0.050 |
Why?
|
| Prolactin | 1 | 2002 | 169 | 0.050 |
Why?
|
| Organ Culture Techniques | 1 | 2002 | 228 | 0.050 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2006 | 517 | 0.050 |
Why?
|
| Hydrocortisone | 1 | 2002 | 401 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2009 | 1900 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 1190 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2002 | 548 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2004 | 898 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 1107 | 0.040 |
Why?
|
| Uterus | 2 | 2010 | 798 | 0.040 |
Why?
|
| Mutation | 3 | 2015 | 15904 | 0.040 |
Why?
|
| Insulin | 1 | 2002 | 1426 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 2112 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2004 | 2105 | 0.030 |
Why?
|
| Estradiol | 3 | 2005 | 828 | 0.030 |
Why?
|
| DNA Adducts | 1 | 1997 | 214 | 0.030 |
Why?
|
| Breast | 1 | 2002 | 1369 | 0.030 |
Why?
|
| Cataract | 2 | 2010 | 236 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2003 | 1716 | 0.030 |
Why?
|
| Anticarcinogenic Agents | 1 | 1997 | 368 | 0.030 |
Why?
|
| Myocardial Ischemia | 2 | 2010 | 400 | 0.030 |
Why?
|
| Proteins | 1 | 2003 | 2029 | 0.030 |
Why?
|
| Mice | 5 | 2012 | 35477 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2013 | 841 | 0.030 |
Why?
|
| Risk | 2 | 2010 | 1937 | 0.030 |
Why?
|
| Stress Fibers | 1 | 2013 | 15 | 0.030 |
Why?
|
| Menopause | 1 | 2013 | 159 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2002 | 5692 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2013 | 185 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2010 | 2585 | 0.030 |
Why?
|
| Mice, Nude | 2 | 2012 | 4331 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2013 | 267 | 0.020 |
Why?
|
| Cytoskeleton | 1 | 2013 | 293 | 0.020 |
Why?
|
| Membrane Transport Proteins | 1 | 2013 | 245 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2002 | 7054 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2010 | 7919 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2012 | 265 | 0.020 |
Why?
|
| Cell Line, Tumor | 3 | 2013 | 14873 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 469 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2013 | 1023 | 0.020 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2010 | 40 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2013 | 1801 | 0.020 |
Why?
|
| Fractures, Spontaneous | 1 | 2010 | 87 | 0.020 |
Why?
|
| Transfection | 2 | 2005 | 3110 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2013 | 677 | 0.020 |
Why?
|
| Thromboembolism | 1 | 2010 | 150 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 1459 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2010 | 188 | 0.020 |
Why?
|
| Anoikis | 1 | 2009 | 63 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2003 | 5416 | 0.020 |
Why?
|
| Kidney | 1 | 1997 | 2105 | 0.020 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2009 | 143 | 0.020 |
Why?
|
| Ovariectomy | 1 | 2009 | 372 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 1003 | 0.020 |
Why?
|
| Liver | 1 | 1997 | 3063 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2006 | 10714 | 0.020 |
Why?
|
| Gene Expression | 2 | 2006 | 3606 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2013 | 7232 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2004 | 5759 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2009 | 667 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 12040 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 2050 | 0.020 |
Why?
|
| Genotype | 1 | 2013 | 4249 | 0.020 |
Why?
|
| Rats | 2 | 2009 | 6404 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2013 | 2163 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2013 | 4906 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2004 | 79 | 0.010 |
Why?
|
| Transcriptome | 1 | 2013 | 1960 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 3924 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2013 | 9044 | 0.010 |
Why?
|
| Fractures, Bone | 1 | 2006 | 311 | 0.010 |
Why?
|
| Benzamides | 1 | 2009 | 1879 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2006 | 517 | 0.010 |
Why?
|
| Cause of Death | 1 | 2006 | 789 | 0.010 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2003 | 174 | 0.010 |
Why?
|
| Response Elements | 1 | 2003 | 192 | 0.010 |
Why?
|
| Receptors, Steroid | 1 | 2004 | 337 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2009 | 1536 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2013 | 9290 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2010 | 4052 | 0.010 |
Why?
|
| Gene Library | 1 | 2003 | 350 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2003 | 364 | 0.010 |
Why?
|
| Biological Transport | 1 | 2003 | 630 | 0.010 |
Why?
|
| Uterine Neoplasms | 1 | 2006 | 576 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 931 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2003 | 1044 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2005 | 2428 | 0.010 |
Why?
|
| Histone Deacetylases | 1 | 2003 | 362 | 0.010 |
Why?
|
| Endometrial Neoplasms | 1 | 2010 | 1385 | 0.010 |
Why?
|
| Aged | 3 | 2013 | 73550 | 0.010 |
Why?
|
| Thrombosis | 1 | 2006 | 743 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2003 | 746 | 0.010 |
Why?
|
| Mammary Glands, Animal | 1 | 2003 | 617 | 0.010 |
Why?
|
| Middle Aged | 3 | 2013 | 90524 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2005 | 1586 | 0.010 |
Why?
|
| Binding Sites | 1 | 2003 | 2249 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 5317 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2004 | 2135 | 0.010 |
Why?
|
| Toremifene | 1 | 1997 | 8 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2003 | 1715 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2003 | 1630 | 0.010 |
Why?
|
| Chromatin | 1 | 2003 | 1044 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2003 | 1306 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1997 | 235 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2003 | 4542 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2006 | 12044 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2003 | 1626 | 0.010 |
Why?
|
| Inflammation | 1 | 2006 | 2492 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2004 | 4006 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 3204 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 6655 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 15282 | 0.010 |
Why?
|
| Disease Progression | 1 | 2006 | 6868 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 6343 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2013 | 33808 | 0.010 |
Why?
|
| Adult | 2 | 2010 | 82174 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2006 | 3707 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 31079 | 0.010 |
Why?
|
| Pregnancy | 1 | 2003 | 8131 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1985 | 3146 | 0.000 |
Why?
|
| Male | 1 | 2006 | 128484 | 0.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1985 | 16720 | 0.000 |
Why?
|